Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Syntex Laboratories is a company.
Key people at Syntex Laboratories.
Syntex Laboratories researches and manufactures synthetic steroid hormones for pharmaceutical applications. The company pioneered efficient chemical synthesis, producing key hormonal compounds from plant sources, notably the Mexican yam. This enabled large-scale progesterone and vital steroid production, forming the basis for numerous therapeutic drugs.
Founded in Mexico in 1944, Syntex began with chemist Russell Marker's groundbreaking work. Marker devised a cost-effective process to convert diosgenin from the cabeza de negro yam into progesterone. This advancement addressed a global steroid precursor shortage, enabling mass production of hormonal drugs; George Rosenkranz later guided its expansion.
Syntex supplied steroid intermediates to the pharmaceutical industry, supporting medical treatments. Its products were fundamental in developing early oral contraceptives and other hormonal therapies, profoundly impacting patient care. The company's vision focused on biochemical innovation to expand access to vital medicines and improve public health.
Key people at Syntex Laboratories.
Syntex Laboratories, originally Syntex S.A., was a pioneering pharmaceutical company founded in Mexico City in 1944, specializing in steroid hormones derived from Mexican yams (barbasco plants).[1][2][5][6] It revolutionized medicine by developing low-cost synthesis of progesterone, cortisone, and the first orally active progestins like norethindrone, leading to early oral contraceptives such as Norinyl (1964) and anti-inflammatories like Naprosyn (1975).[1][2][3][6] The company expanded into diagnostics (Syva), veterinary drugs, agribusiness, dental products, and beauty care, achieving rapid growth before its acquisition by Roche in 1994.[1][2][4]
Syntex served global healthcare markets, addressing chronic conditions like arthritis, heart disease, allergies, and reproductive health, while solving high-cost steroid production through innovative chemistry from plant sources.[2][3][5] Its growth momentum peaked in the 1960s-1970s with U.S. entry (1947), Panama incorporation (1957), Palo Alto headquarters (1964), and acquisitions, though it faced FDA challenges in the 1970s.[1][4]
Syntex trace its roots to 1944 when American chemist Russell Marker, frustrated with U.S. industry, partnered with Hungarian Emeric Somlo and German Federico Lehmann of Laboratorios Hormona to form Syntex S.A. in Mexico City.[1][2][3][5][6] Marker had developed a breakthrough process to synthesize progesterone from inexpensive Mexican yams, producing kilos at scale after leaving his prior role.[2][5] Disagreements over compensation led Marker to depart shortly after, taking his notebooks, but the company quickly recruited George Rosenkranz and, in 1949, Carl Djerassi—later dubbed the "father of the pill"—who drove steroid innovations.[3][6]
Early traction came from selling progesterone at $50/gram by 1945, fueling cortisone synthesis in 1951 and the first oral contraceptive progestin (norethindrone) that year.[1][3][5][6] Pivotal moments included U.S. market entry via Chemical Specialties (1947), public listing in Panama (1957), and relocation to Palo Alto (1964), marking its evolution from bulk chemicals to branded pharmaceuticals.[1][2]
Syntex rode the mid-20th-century steroid hormone revolution, capitalizing on post-WWII demand for affordable cortisone (for arthritis) and progesterone derivatives amid booming reproductive health needs.[3][5] Timing was ideal: Marker’s yam-based process democratized steroids when natural extraction was scarce and expensive, influencing global pharma like Glaxo’s licensing of hecogenin routes for blockbusters (e.g., Betnovate).[3] Market forces favored it—Mexico’s lax regulations, yam abundance, and U.S. FDA bans on alternatives like DES boosted veterinary lines.[4][5]
It shaped the ecosystem by kickstarting Mexico’s steroid industry, inspiring competitors, and advancing oral contraceptives, which transformed women’s health and family planning worldwide.[2][3][6] Syntex’s alumni, like ALZA founder Alex Zaffaroni, spawned spin-offs, while its diagnostics and agribusiness arms diversified pharma beyond pills.[1][7]
Though defunct since Roche’s 1994 acquisition, Syntex’s legacy endures in modern endocrinology, generics, and hormone therapies derived from its breakthroughs.[2] Post-acquisition, its innovations integrated into Roche’s portfolio, influencing ongoing steroid drug development. Trends like biotech revival of plant-based synthesis and precision reproductive medicine could echo Syntex’s model, potentially inspiring new ventures in sustainable pharma. Its story—from yam fields to the pill—remains a blueprint for chemistry-driven disruption in healthcare.[3][5]
